These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34136742)

  • 21. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
    Zavalishina L; Tsimafeyeu I; Povilaitite P; Raskin G; Andreeva Y; Petrov A; Kharitonova E; Rumyantsev A; Pugach I; Frank G; Tjulandin S
    Virchows Arch; 2018 Dec; 473(6):719-724. PubMed ID: 30209552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
    Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
    Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.
    Scheel AH; Dietel M; Heukamp LC; Jöhrens K; Kirchner T; Reu S; Rüschoff J; Schildhaus HU; Schirmacher P; Tiemann M; Warth A; Weichert W; Fischer RN; Wolf J; Buettner R
    Mod Pathol; 2016 Oct; 29(10):1165-72. PubMed ID: 27389313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability.
    Ahn S; Woo JW; Kim H; Cho EY; Kim A; Kim JY; Kim C; Lee HJ; Lee JS; Bae YK; Kwon Y; Kim WS; Park SY
    J Breast Cancer; 2021 Jun; 24(3):266-279. PubMed ID: 34128367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer.
    Xu H; Lin G; Huang C; Zhu W; Miao Q; Fan X; Wu B; Zheng X; Lin X; Jiang K; Hu D; Li C
    Sci Rep; 2017 Dec; 7(1):16956. PubMed ID: 29209070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
    Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
    Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays.
    Dabbagh TZ; Sughayer MA
    Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):462-466. PubMed ID: 33480602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays.
    Beck KS; Kim SJ; Kang JH; Han DH; Jung JI; Lee KY
    Thorac Cancer; 2019 Jul; 10(7):1612-1618. PubMed ID: 31237079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review.
    Koomen BM; Badrising SK; van den Heuvel MM; Willems SM
    Histopathology; 2020 May; 76(6):793-802. PubMed ID: 31793055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
    Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
    J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
    Guo H; Ding Q; Gong Y; Gilcrease MZ; Zhao M; Zhao J; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
    Breast Cancer Res; 2020 Jun; 22(1):69. PubMed ID: 32576238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges facing pathologists evaluating PD-L1 in head & neck squamous cell carcinoma.
    Girolami I; Pantanowitz L; Barberis M; Paolino G; Brunelli M; Vigliar E; Munari E; Satturwar S; Troncone G; Eccher A
    J Oral Pathol Med; 2021 Oct; 50(9):864-873. PubMed ID: 34157159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.
    Reisenbichler ES; Han G; Bellizzi A; Bossuyt V; Brock J; Cole K; Fadare O; Hameed O; Hanley K; Harrison BT; Kuba MG; Ly A; Miller D; Podoll M; Roden AC; Singh K; Sanders MA; Wei S; Wen H; Pelekanou V; Yaghoobi V; Ahmed F; Pusztai L; Rimm DL
    Mod Pathol; 2020 Sep; 33(9):1746-1752. PubMed ID: 32300181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection.
    Cha YJ; Kim D; Bae SJ; Ahn SG; Jeong J; Lee HS; Jeon S; Yoo TK; Park WC; Yoon CI
    Sci Rep; 2021 Oct; 11(1):19555. PubMed ID: 34599199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice.
    Villaruz LC; Ancevski Hunter K; Kurland BF; Abberbock S; Herbst C; Dacic S
    Histopathology; 2019 Jan; 74(2):269-275. PubMed ID: 30105871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
    Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
    Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma.
    Sakane T; Murase T; Okuda K; Takino H; Masaki A; Oda R; Watanabe T; Kawano O; Haneda H; Moriyama S; Saito Y; Yamada T; Nakanishi R; Inagaki H
    Oncotarget; 2018 Jan; 9(6):6993-7009. PubMed ID: 29467945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.
    Miyakoshi J; Yazaki S; Shimoi T; Onishi M; Saito A; Kita S; Yamamoto K; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Fujiwara Y; Yoshida M; Yonemori K
    Virchows Arch; 2023 Dec; 483(6):855-863. PubMed ID: 37668667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.
    Reis H; Serrette R; Posada J; Lu V; Chen YB; Gopalan A; Fine SW; Tickoo SK; Sirintrapun SJ; Iyer G; Funt SA; Teo MY; Rosenberg JE; Bajorin DF; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
    Am J Surg Pathol; 2019 Jul; 43(7):920-927. PubMed ID: 31135485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.